Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paracetamol + morphine + tramadol is a multimodal analgesic combination regimen being evaluated for the management of pain during vaso-occlusive crises (VOC) in adult patients with sickle cell disease. This combination combines paracetamol (acetaminophen), a non-opioid analgesic and antipyretic, with morphine, a strong mu-opioid receptor agonist, and tramadol, a weak mu-opioid agonist and monoamine reuptake inhibitor. By combining these agents with different mechanisms of action, the regimen aims to optimize pain control and reduce overall morphine consumption, thereby minimizing dose-dependent opioid side effects such as respiratory depression, sedation, and constipation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paracetamol + morphine + tramadol.